Community-Based Point-of-Care Screening for Hepatitis B Virus and Hepatocellular Carcinoma in Rural Tanzania
The American Journal of Tropical Medicine and Hygiene · 2025
DOI: 10.4269/ajtmh.24-0341 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2025. Verfasst von Manaswita Tappata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota, Minneapolis, Minnesota. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Rural Population, Hepatitis B. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS.
Abstract (Originalsprache)
Sub-Saharan Africa has a high burden of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC). The lack of surveillance programs has led to low rates of diagnosis and treatment, particularly in rural areas. We conducted mobile HBV-HCC screening clinics in rural Tanzania between March 2021 and February 2023. After undergoing informed consent, patients completed a questionnaire about HBV. A rapid point-of-care (POC) assay measured HBV surface antigen (HBsAg), and HBsAg-positive patients underwent POC ultrasound to screen for HCC and POC hepatitis C (HCV) antibody testing. The primary outcome was number of HBV diagnoses, and the secondary outcome was prevalence of liver masses in HBsAg-positive individuals. Data were analyzed with descriptive statistics. Five hundred and one patients were screened for HBV; 63% ( n = 303) were female with median (interquartile range [IQR]) age of 40 (28–55) years. Only 6% ( n = 30) reported being vaccinated against HBV, 92% ( n = 453) reported no vaccination, and 2% ( n = 12) did not know their vaccination status. Seventy-six percent ( n = 340) did not know they should get vaccinated, and 4% ( n = 16) reported that vaccination was too expensive. Two percent ( n = 11) of patients were positive for HBsAg, with 55% ( n = 6) of those being female with median (IQR) age of 36 (34–43) years. None of the HBsAg-positive patients reported being vaccinated against HBV, and all were negative for HCV. On ultrasound, one patient had a liver mass, and another had ascites. We demonstrated that community-based HBV and HCC screening can be implemented in Africa with local partnerships, and this model could be used to promote awareness and improve early detection of disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
- Department of Emergency Medicine, University of California, San Francisco, San Francisco, California.
- Department of Medicine, Arusha Lutheran Medical Center, Arusha, Tanzania.
- School of Medicine, University of California, Davis, Sacramento, California.
- Department of Surgery, Arusha Lutheran Medical Center, Arusha, Tanzania.
- Department of Emergency Medicine, University of California Davis Health, Sacramento, California.
Förderung
- FIC NIH HHS
Zitieren
APA
Tappata, M., Ford, J., Kayandabila, J., Morrison, J., Seth, S., Lyimo, B., May, L., & Debes, J. D. (2025). Community-Based Point-of-Care Screening for Hepatitis B Virus and Hepatocellular Carcinoma in Rural Tanzania. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.24-0341
Vancouver
Tappata M, Ford J, Kayandabila J, Morrison J, Seth S, Lyimo B, et al. Community-Based Point-of-Care Screening for Hepatitis B Virus and Hepatocellular Carcinoma in Rural Tanzania. The American Journal of Tropical Medicine and Hygiene. 2025. doi:10.4269/ajtmh.24-0341
BibTeX
@article{Tappata2025,
author = {Tappata, Manaswita and Ford, James and Kayandabila, Johnstone and Morrison, Joseph and Seth, Samwel and Lyimo, Benson and May, Larissa and Debes, Jose D},
title = {Community-Based Point-of-Care Screening for Hepatitis B Virus and Hepatocellular Carcinoma in Rural Tanzania},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2025},
doi = {10.4269/ajtmh.24-0341}
}
EUVIMED